Combined Index to USP 41 and NF 36, Volumes 1–5, Including Second Supplement

Total Page:16

File Type:pdf, Size:1020Kb

Combined Index to USP 41 and NF 36, Volumes 1–5, Including Second Supplement Combined Index to USP 41 and NF 36 Abaca-Aceto I-1 Combined Index to USP 41 and NF 36, Volumes 1–5, including Second Supplement Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 41±NF 36 and its First and Second Supplement. This index is repeated in its entirety in each volume. 1±2302 Volume 1 2303±4414 Volume 2 4415±5658 Volume 3 5659±6698 Volume 4 6699±8228 Volume 5 8229±8720 First Supplement 8721±9256 Second Supplement Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and caffeine tablets, 44 and pseudoephedrine hydrochloride A capsules, 36 tablets, 64 and (salts of) chlorpheniramine, oral solution, 37 Abacavir dextromethorphan, and for effervescent oral solution, 37 oral solution, 19 pseudoephedrine, capsules containing at suppositories, 38 sulfate, 23 least three of the following, 45 oral suspension, 39, 8264 tablets, 20 and (salts of) chlorpheniramine, tablets, 39, 8266 and lamivudine tablets, 21 dextromethorphan, and extended-release tablets, 40 Abiraterone pseudoephedrine, oral powder and tramadol hydrochloride oral acetate, 24 containing at least three of the suspension, 4157 acetate tablets, 26 following, 47 Acetanilide, 5664 Absolute and (salts of) chlorpheniramine, Acetate alcohol, 5666 dextromethorphan, and methyl, 5706 ether, 5664 pseudoephedrine, oral solution Acetate buffer, 5676 Absorbable containing at least three of the TS, 5750 dusting powder, 1457 following, 49 Acetazolamide, 65 gelatin film, 1929 and (salts of) chlorpheniramine, for injection, 66 gelatin sponge, 1929 dextromethorphan, and oral suspension, 68 surgical suture, 3901 pseudoephedrine, tablets containing at tablets, 68 Absorbent least three of the following, 51 Acetic acid, 5181, 5664 cotton, 5664 chlorpheniramine maleate, and ammonium acetate buffer TS, 5750 gauze, 1927 dextromethorphan hydrobromide diluted, 5181, 5664, 5690 Acacia, 5179 tablets, 53 double-normal (2 N), 5762 syrup, 5179 and codeine phosphate capsules, 55 glacial, 69, 5664, 5697 Acamprosate calcium, 8263 and codeine phosphate oral solution, 56 glacial, TS, 5750, 5754 Acarbose, 28 and codeine phosphate oral suspension, and hydrocortisone otic solution, 2062 Acebutolol hydrochloride, 29 57 irrigation, 69 capsules, 30 and codeine phosphate tablets, 59 metaphosphoric, TS, 5756 Acepromazine maleate, 32 dextromethorphan hydrobromide, otic solution, 70 injection, 33 doxylamine succinate, and strong, TS, 5750 tablets, 34 pseudoephedrine hydrochloride oral 1 M TS, 5750 Acesulfame potassium, 5180 solution, 60 2 M TS, 5750 Acetal, 5664 and diphenhydramine citrate tablets, 61 Acetic acid in peptides, 6246 Acetaldehyde, 5664 diphenhydramine hydrochloride, and 0.008 M Acetic acid TS, 5750 TS, 5750 pseudoephedrine hydrochloride tablets, 0.3 N Acetic acid TS, 5750 Acetaldehyde ammonia trimer trihydrate, 63 Acetic anhydride, 5664 5664 and hydrocodone bitartrate tablets, 2053 Acetohydroxamic acid, 70 Acetaminophen, 34 isometheptene mucate, and tablets, 71 aspirin and caffeine tablets, 42 dichloralphenazone capsules, 2251 Acetone, 5182, 5664 and aspirin tablets, 41 and oxycodone capsules, 3107 anhydrous, 5664 butalbital and caffeine capsules, 596 and oxycodone tablets, 3108 neutralized, 5664, 5750, 5752 butalbital and caffeine tablets, 597 and pentazocine tablets, 3221 I-2 Aceto-Alumi Combined Index to USP 41 and NF 36 Acetonitrile, 5664 Epinephrine inhalation, 1530, 8826 tertiary butyl, 5666 spectrophotometric, 5664 Ergotamine tartrate inhalation, 1558, 8827 Alcoholic Acetophenone, 5664 Fluticasone propionate and salmeterol ammonia TS, 5750 p-Acetotoluidide, 5664 inhalation, 1847 mercuric bromide TS, 5750 Acetylacetone, 5664 Fluticasone propionate inhalation, 1831 potassium hydroxide TS, 5750 Acetyl chloride, 5664 Inhalation and nasal drug products: potassium hydroxide TS 2, 5758 Acetylcholine chloride, 72, 5665 aerosols, sprays, and powdersÐ TS, 5750 for ophthalmic solution, 73 performance quality tests 〈601〉, 6327 Alcoholometric table, 5861 Acetylcysteine, 74 Isoetharine mesylate inhalation, 2245, Aldehyde dehydrogenase, 5666 Acetylcysteine 8868 Alendronate sodium, 109 compounded solution, 75 Isoproterenol hydrochloride inhalation, tablets, 110 and isoproterenol hydrochloride inhalation 2259, 8869 Alfadex, 5189 solution, 76 Isoproterenol hydrochloride and Alfentanil solution, 74 phenylephrine bitartrate inhalation, hydrochloride, 112 N-Acetylglucosamine, 4417 2262, 8870 injection, 113 3-Acetylthio-2-methylpropanoic acid, 5665 Isoproterenol sulfate inhalation, 2264 Alfuzosin hydrochloride, 114 Acetyltributyl citrate, 5183 Lidocaine topical, 2410 extended-release tablets, 115 Acetyltriethyl citrate, 5183 Metaproterenol sulfate inhalation, 2607, Alginates assay 〈311〉, 6170 N-Acetyltyrosine, 4418 8351 Alginic acid, 5190 N-Acetyl-L-tyrosine ethyl ester, 5665 Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 5666 Acid topical, 3350 Alkaline acrylic, 5665 Povidone±iodine topical, 3392 borate buffer, 5676 alpha lipoic, 4740 Terbutaline sulfate inhalation, 3986, 8429 cupric citrate TS, 5750 dehydroacetic, 5320 Thimerosal topical, 4056 cupric citrate TS 2, 5750 ferric chloride TS, 5750 Tolnaftate topical, 4135 cupric iodide TS, 5750 ferrous sulfate TS, 5750 Triamcinolone acetonide topical, 4186 cupric tartrate TS, 5750 Folic, compounded oral soultion, 1866 mercuric-potassium iodide TS, 5750 iminodiacetic, 5701 phosphatase enzyme, 5666 stannous chloride TS, 5750 picrate TS, 5750 stannous chloride TS, stronger, 5750 Agar, 5185, 5665 pyrogallol TS, 5758 Acid-neutralizing capacity 〈301〉, 6169 Agarose, 5665 sodium hydrosulfite TS, 5751 Acidulated phosphate and sodium fluoride Air, medical, 91 Alkyl (C12-15) benzoate, 5191 topical solution, 3791, 8423 Air-helium certified standard, 5665 Alkylphenoxypolyethoxyethanol, 5666 Acitretin, 77 Alanine, 92 Allantoin, 120 capsules, 78 L-Alanyl-L-glutamine, 4420 Allopurinol, 121 Storage and transportation of investigational Albendazole, 93 oral suspension, 123 drug products 〈1079.1〉, 6702, 7130, 7622 oral suspension, 93 tablets, 123 Acrylic acid, 5665 tablets, 94 Allyl isothiocyanate, 124 Activated Albumen TS, 5750 Almond oil, 5191 alumina, 5665 Albumin Almotriptan charcoal, 859, 5665 bovine serum, 5665 tablets, 127 magnesium silicate, 5665 human, 95 Almotriptan malate, 124 Acyclovir, 80 rAlbumin human, 5186 Aloe, 129 capsules, 80 Albuterol, 95 Alpha for injection, 81 sulfate, 100 lipoic acid, 4740 ointment, 82 tablets, 96 Alpha-chymotrypsin, 5666 oral suspension, 83 extended-release tablets, 97 Alpha cyclodextrin hydrate, 5666 tablets, 84 Alclometasone dipropionate, 100 Alpha-(2-(methylamino)ethyl)benzyl alcohol, Adamantane, 5665 cream, 102 5666 Adapalene, 85 ointment, 102 Alphanaphthol, 5666 gel, 87 Alcohol, 103, 5665 Alphazurine 2G, 5745 Ademetionine disulfate tosylate, 4419 70 percent, 80 percent, and 90 percent, Alprazolam, 130 Adenine, 88 5665 oral suspension, 131 sulfate, 5665 absolute, 5666 tablets, 131, 8757 Adenosine, 89 aldehyde-free, 5666 extended-release tablets, 133 injection, 90 alpha-(2-(methylamino)ethyl)benzyl, 5666 orally disintegrating tablets, 136 Adipic acid, 5184, 5665 amyl, 5666 Alprenolol hydrochloride, 5666 Admissions tert-amyl, 5666, 5669, 5702 Alprostadil, 138 to NF 36, 5167 butyl, 5229 injection, 140 to USP 41, xxxiii dehydrated, 105, 5666, 5686 Alteplase, 141 dehydrated isopropyl, 5666 for injection, 144 denaturated, 5666 Alternative microbiological sampling methods denaturated, TS, 5753 for nonsterile inhaled and nasal products determination 〈611〉, 6358 〈610〉, 6356 Aerosol in dextrose injection, 107 Altretamine, 146 Bacitracin and polymyxin B sulfate topical, diluted, 5188, 5666 capsules, 147 439 injection, dehydrated, 107 Alum, 5666 Benzocaine, butamben, and tetracaine isobutyl, 5666 ammonium, 148, 5666 hydrochloride topical, 479 isopropyl, 5666 potassium, 148, 5719 Benzocaine and menthol topical, 484 methyl, 5666 Alumina, 5666 Benzocaine topical, 470 neutralized, 5666, 5710 activated, 5665, 5666, 5669 Dexamethasone sodium phosphate phenol TS, 5750 anhydrous, 5666 inhalation, 1203, 8317 n-propyl, 5666 aspirin, codeine phosphate, and magnesia Epinephrine bitartrate inhalation, 1533, rubbing, 108 tablets, 380 8826 secondary butyl, 5666 aspirin, and magnesia tablets, 373 Combined Index to USP 41 and NF 36 Alumi-Ammon I-3 Alumina (continued) Aluminum chloride, 5667 oral solution, 229 aspirin, and magnesium oxide tablets, 375 Aluminum sulfate rectal solution, 231 magnesia, and calcium carbonate and calcium acetate for topical solution, suppositories, 231 chewable tablets, 152 176 tablets, 232 magnesia, calcium carbonate, and Amantadine hydrochloride, 194 delayed-release tablets, 234 simethicone chewable tablets, 153 capsules, 195 3-Amino-1-propanol, 5668 magnesia, and calcium carbonate oral oral solution, 196 3-Aminopropionic acid, 5668 suspension, 151 Amaranth, 5667 Aminosalicylate sodium, 235 magnesia, and simethicone oral TS, 5751 tablets, 237 suspension, 155 Amcinonide, 196 Aminosalicylic acid, 238 magnesia, and simethicone chewable cream, 197 tablets, 239 tablets, 157 ointment, 198 3-Aminosalicylic acid, 5668 and magnesia oral suspension, 149 American ginseng, 4422 Amiodarone and magnesia tablets, 150 capsules, 4426 hydrochloride injection, 243 magnesium carbonate, and magnesium extract, powdered, 4425 Amiodarone hydrochloride, 240 oxide tablets, 160 powdered, 4423 oral suspension, 245 and magnesium carbonate oral suspension, tablets, 4428 Amitraz, 245 158 Amifostine, 198 concentrate for dip, 247 and magnesium carbonate tablets, 159 for injection, 199 Amitriptyline
Recommended publications
  • 30 Day Change Notice Effective Date
    30 Day Change Notice Effective Date: January 1st, 2021 NEW PREFERRED DRUGS THERAPEUTIC CLASS NO PA REQUIRED PREFERRED Central Nervous System (CNS) Agents: Anticonvulsants Clobazam (Generic of Onfi) Central Nervous System (CNS) Agents: Multiple Aubagio EndocrineSclerosis Agents: Osteoporosis-Bone Ossification Forteo Enhancers Gastrointestinal Agents: Anti-Emetics Bonjesta Genitourinary Agents: Benign Prostatic Hyperplasia Alfuzosin (Generic of Uroxatral) Dutasteride (Generic of Avodart) Genitourinary Agents: Electrolyte Depleter Agents Sevelamer (Generic of Renagel and Renvela) Infectious Disease Agents: Antibiotics-Macrolides Eryped Infectious Disease Agents: Antivirals-HIV Atazanavir Sulfate Oral Powder (Generic of Reyataz) Tivicay PD Infectious Disease Agents: Antibiotics-Tetracyclines Vibramycin Suspension (no PA Required for age 12 or under) Ophthalmic Agents: Antibiotics and Antibiotic -Steroid Neomycin/Polymyxin/Bacitracin/Hydrocortisone Ointment Combination Drops and Ointments Ophthalmic Agents: Glaucoma Agents Dorzolamide/Timolol (Generic of Cosopt PF) NEW CLINICAL PA REQUIRED “PREFERRED” DRUGS THERAPEUTIC CLASS CLINICAL PA REQUIRED PREFERRED Blood Formation, Coagulation, and Thrombosis Agents: Corifact Hemophilia Factors Immunomodulator Agents for Systemic Inflammatory Taltz Disease Immunomodulator Agents for Systemic Inflammatory Xeljanz 5mg Disease NEW STEP THERAPY REQUIRED “PREFERRED” THERAPEUTIC CLASS STEP THERAPY REQUIRED “PREFERRED” Central nervous System (CNS) Agents: Anti-Migraine, Aimovig Prophylaxis Treatment Ajovy
    [Show full text]
  • Active Pharmaceutical Ingredients
    Active Pharmaceutical Ingredients Catalog HPD-5E ® CREATING A HEALTHY WORLDTM Active Pharmaceutical Ingredients (APIs) Available for International Markets Human Pharmaceutical Department www.Pharmapex.net Catalog HPD-5E *Not all products referred to on this site are available in all countries and our products are subject to different regulatory requirements depending on the country of use. Consequently, certain sections of this site may be indicated as being intended only for users in specic countries. Some of the products may also be marketed under different trade names. You should not construe anything on this site as a promotion or solicitation for any product or for the use of any product that is not authorized by the laws and regulations of your country of residence. For inquiries about the availability of any specic product in your country, you may simply contact us at [email protected]. **Products currently covered by valid US Patents may be offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk. ©2016, Pharmapex USA, A member of Apex Group of Companies, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: + 1.619.881.0035 ACTIVE PHARMACEUTICAL [email protected] CREATING A HEALTHY WORLD™ www.Pharmapex.net INGREDIENTS About Pharmapex’s Human Pharmaceuticals Department: Pharmapex’s Human Pharmaceuticals Department (HPD) is a leading source for high-quality Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs) in various markets across the globe. With an extensive product portfolio, our consortium of companies is dedicated to addressing and solving the most important medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes).
    [Show full text]
  • INTEGRIS Formulary July 2017
    INTEGRIS Formulary July 2017 Foreword FORMULARY EXCLUDED THERAPEUTIC DRUG This document represents the efforts of the MedImpact Healthcare Systems THERAPEUTIC DRUGS CLASS Pharmacy and Therapeutics (P & T) and Formulary Committees to provide ALTERNATIVES physicians and pharmacists with a method to evaluate the safety, efficacy and cost- clindamycin/tretinoin, ACNE AGENTS, effectiveness of commercially available drug products. A structured approach to the VELTIN drug selection process is essential in ensuring continuing patient access to rational ZIANA TOPICAL drug therapies. The ultimate goal of the MedPerform Formulary is to provide a morphine sulfate ER process and framework to support the dynamic evolution of this document to guide tablets, oxycodone ANALGESICS, KADIAN prescribing decisions that reflect the most current clinical consensus associated ER, NUCYNTA, NARCOTICS with drug therapy decisions. NUCYNTA ER ANALGESICS, This is accomplished through the auspices of the MedImpact P & T and Formulary BELBUCA BUTRANS PATCH Committees. These committees meet quarterly and more often as warranted to NARCOTICS ensure clinical relevancy of the Formulary. To accommodate changes to this ABSTRAL, document, updates are made accessible as necessary. FENTORA, fentanyl citrate ANALGESICS, LAZANDA, lozenge NARCOTICS As you use this Formulary, you are encouraged to review the information and ONSOLIS, provide your input and comments to the MedImpact P & T and Formulary SUBSYS Committees. immediate-release GRALISE ANTICONVULSANTS The MedImpact P & T
    [Show full text]
  • Printed Formulary Catalog Basic
    Scripps Health Formulary July 2016 Foreword Pharmacy and Therapeutics Committee. MedImpact approves such multi- This document represents the efforts of the MedImpact Healthcare Systems source drugs for addition to the MAC list based on the following criteria: Pharmacy and Therapeutics (P & T) and Formulary Committees to provide physicians A multi-source drug product manufactured by at least one (1) nationally and pharmacists with a method to evaluate the safety, efficacy and cost-effectiveness marketed company. of commercially available drug products. A structured approach to the drug selection At least one (1) of the generic manufacturer’s products must have an “A” process is essential in ensuring continuing patient access to rational drug therapies. rating or the generic product has been determined to be unassociated with The ultimate goal of the Portfolio Formulary is to provide a process and framework to efficacy, safety or bioequivalency concerns by the MedImpact P & T support the dynamic evolution of this document to guide prescribing decisions that Committee. reflect the most current clinical consensus associated with drug therapy decisions. Drug product will be approved for generic substitution by the MedImpact P & T Committee. This is accomplished through the auspices of the MedImpact P & T and Formulary Committees. These committees meet quarterly and more often as warranted to ensure This list is reviewed and updated periodically based on the clinical literature and clinical relevancy of the Formulary. To accommodate changes to this document, pharmacokinetic characteristics of currently available versions of these drug updates are made accessible as necessary. products. As you use this Formulary, you are encouraged to review the information and provide If a member or physician requests a brand name product in lieu of an approved your input and comments to the MedImpact P & T and Formulary Committees.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Index B Alphabetical List of Pharmaceutical Product Names
    INDEX B ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES PRODUCT NAME Page PRODUCT NAME Page 292 97 ACYCLOVIR 17 3TC (EDS) 14 ACYCLOVIR 17 5-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18 ABACAVIR SO4 13 ADALAT XL 57 ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220 ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206 ABATACEPT 220 ADCIRCA (EDS) 89 ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18 ACARBOSE 187 ADHESIVE WIPES (EDS) 239 ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231 ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33 ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33 ACCOLATE (EDS) 232 AGGRENOX (EDS) 87 ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221 ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32 ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234 ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234 ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82 ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82 ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148 ACCU-CHEK MOBILE 142 ALDARA (EDS) 209 ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220 ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220 ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181 ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220 ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221 ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158 ACCUPRIL 79 ALPHAGAN 157 ACCURETIC 80 ALPHAGAN P 157 ACCUTANE 209 ALPRAZOLAM 134 ACCUTREND 142 ALPRAZOLAM 134 ACEBUTOLOL 48 ALTACE 80 ACEBUTOLOL HCL 48 " 81
    [Show full text]
  • Metal Complexes of Quinolone Antibiotics and Their Applications: an Update
    Molecules 2013, 18, 11153-11197; doi:10.3390/molecules180911153 OPEN ACCESS molecules ISSN 1420-3049 www.mdpi.com/journal/molecules Review Metal Complexes of Quinolone Antibiotics and Their Applications: An Update Valentina Uivarosi Department of General and Inorganic Chemistry, Faculty of Pharmacy, Carol Davila University of Medicine and Pharmacy, 6 Traian Vuia St, Bucharest 020956, Romania; E-Mail: [email protected]; Tel.: +4-021-318-0742; Fax: +4-021-318-0750 Received: 8 August 2013; in revised form: 2 September 2013 / Accepted: 2 September 2013 / Published: 11 September 2013 Abstract: Quinolones are synthetic broad-spectrum antibiotics with good oral absorption and excellent bioavailability. Due to the chemical functions found on their nucleus (a carboxylic acid function at the 3-position, and in most cases a basic piperazinyl ring (or another N-heterocycle) at the 7-position, and a carbonyl oxygen atom at the 4-position) quinolones bind metal ions forming complexes in which they can act as bidentate, as unidentate and as bridging ligand, respectively. In the polymeric complexes in solid state, multiple modes of coordination are simultaneously possible. In strongly acidic conditions, quinolone molecules possessing a basic side nucleus are protonated and appear as cations in the ionic complexes. Interaction with metal ions has some important consequences for the solubility, pharmacokinetics and bioavailability of quinolones, and is also involved in the mechanism of action of these bactericidal agents. Many metal complexes with equal or enhanced antimicrobial activity compared to the parent quinolones were obtained. New strategies in the design of metal complexes of quinolones have led to compounds with anticancer activity.
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    The Organic Chemistry of Drug Synthesis VOLUME 2 DANIEL LEDNICER Mead Johnson and Company Evansville, Indiana LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS, New York • Chichester • Brisbane • Toronto Copyright © 1980 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging in Publication Data: Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." 1. Chemistry, Medical and pharmaceutical. 2. Drugs. 3. Chemistry, Organic. I. Mitscher, Lester A., joint author. II. Title. RS421 .L423 615M 91 76-28387 ISBN 0-471-04392-3 Printed in the United States of America 10 987654321 It is our pleasure again to dedicate a book to our helpmeets: Beryle and Betty. "Has it ever occurred to you that medicinal chemists are just like compulsive gamblers: the next compound will be the real winner." R. L. Clark at the 16th National Medicinal Chemistry Symposium, June, 1978. vii Preface The reception accorded "Organic Chemistry of Drug Synthesis11 seems to us to indicate widespread interest in the organic chemistry involved in the search for new pharmaceutical agents. We are only too aware of the fact that the book deals with a limited segment of the field; the earlier volume cannot be considered either comprehensive or completely up to date.
    [Show full text]
  • | Secretion !------Cortisol Cortisol US 7,053,228 B2 Page 2
    US007053228B2 (12) United States Patent (10) Patent No.: US 7,053,228 B2 Burton et al. (45) Date of Patent: May 30, 2006 (54) SULFUR ANALOGUES OF (52) U.S. Cl. ...................... 552/512; 514/179; 514/180; 21-HYDROXY-6,19-OXIDOPROGESTERONE 552/510; 549/29: 549/41 (21OH-60P). FOR TREATING EXCESS OF (58) Field of Classification Search ................ 514/179, GLUCOCORTICODS 514/180, 181: 552/653,510,512; 549/41 (75) Inventors: Gerardo Burton, Prov. de Buenos See application file for complete search history. Aires (AR); Carlos P. Lantos, Buenos Aires (AR); Adriana Silvia Veleiro, (56) References Cited Martinez (AR) U.S. PATENT DOCUMENTS (73) Assignee: Applied Research Systems ARS Holding N.V., Curacao (NL) 6,303,591 B1 * 10/2001 Burton et al. ............... 514f179 FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 EP O 348 910 1, 1990 U.S.C. 154(b) by 148 days. EP O 903 146 3, 1999 OTHER PUBLICATIONS (21) Appl. No.: 10/363,860 “Synthesis of 21-hydroxy-11, 19-oxidopregn-4-ene-320 (22) PCT Filed: Sep. 17, 2001 dione and 21-hydroxy-6, 19-oxidopregn-4-ene-320-dione': Steroids vol. 60, No. 3, pp. 268-271, 1995.* (86). PCT No.: PCT/EPO1/10750 (Continued) S 371 (c)(1), (2), (4) Date: Aug. 20, 2003 Primary Examiner Sabiha Qazi (74) Attorney, Agent, or Firm Oblon, Spivak, McClelland, (87) PCT Pub. No.: WO02/22647 Maier & Neustadt, P.C. PCT Pub. Date: Mar. 21, 2002 (57) ABSTRACT (65) Prior Publication Data The present invention is related to novel 21-hydroxy-6.19 US 2004/002984.6 A1 Feb.
    [Show full text]
  • Bacitracin B:0050 Medical Surveillance: Evaluation by a Qualified Allergist
    B Bacitracin B:0050 Medical Surveillance: Evaluation by a qualified allergist. Kidney function tests. First Aid: In case of large-scale exposure, the directions for Molecular Formula: C H N O S 66 103 17 16 medicines (nonspecific, n.o.s.) would be applied as follows: Synonyms: Ayfivin; Baciguent; Baci-Jel; Baciliquin; Move victim to fresh air; call emergency medical care. If Bacitek ointment; Fortracin; Parentracin; Penitracin; not breathing, give artificial respiration. If breathing is diffi- Topitracin; Zutracin cult, give oxygen. In case of contact with material, immedi- CAS Registry Number: 1405-87-4 ® ately flush skin or eyes with running water for at least RTECS Number: CP0175000 15 min. Speed in removing material from skin is of extreme UN/NA & ERG Number: UN3249 (medicine, solid, toxic, importance. Remove and isolate contaminated clothing and n.o.s.)/151 shoes at the site. Keep victim quiet and maintain normal EC Number: 215-786-2 body temperature. Effects may be delayed; keep victim Regulatory Authority and Advisory Bodies under observation. Listed on the TSCA inventory. Storage: Color Code—Green: General storage may be used. List of Acutely Toxic Chemicals, Chemical Emergency Shipping: The DOT category of medicine, solid, toxic, n.o.s. Preparedness Program (EPA) and formerly on CERCLA/ calls for the label of “POISONOUS/TOXIC MATERIALS.” SARA 40CFR302, Table 302.4 Extremely Hazardous Bacitracin would fall in Hazard Class 6.1 and in Packing Substances List. Dropped from listing in 1988. Group III. Listed on Canada’s DSL List. Spill Handling: Evacuate and restrict persons not wearing WGK (German Aquatic Hazard Class): No value assigned.
    [Show full text]
  • The Σ1 Receptor Engages the Redox-Regulated HINT1 Protein to Bring Opioid
    Page 1 of 110 Original Research Communication The σ1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA receptor negative control María Rodríguez-Muñoz1, Pilar Sánchez-Blázquez1, Raquel Herrero-Labrador1, Ricardo Martínez-Murillo1, Manuel Merlos2, José Miguel Vela2, Javier Garzón1 1Cajal Institute, Consejo Superior de Investigaciones Científicas (CSIC), Avenida Doctor Arce, 37. 28002 Madrid, Spain. 2Drug Discovery & Preclinical Development, Esteve. Scientific Park of Barcelona, Bardiri y Reixac 4-8, 08028, Barcelona, Spain. Running head: σ1R engages NMDAR control on MOR Correspondence to: Javier Garzón. Neurofarmacología, Instituto Cajal, Avenida Doctor Arce 37, 28002 Madrid, Spain. Tel: 34 91 5854733, Fax: 34 91 5854754. E- mail: [email protected] Antioxidants & Redox Signaling Word count: 6950 Reference number: 70 Grayscale Illustrations: Figures 5, 6, 8 and 9 Color Illustrations: Figures 3 and 4 Color online, B&W print: Figures 1, 2, 7, and 10 The 1 receptor engages the redox-regulated HINT1 protein to bring opioid analgesia under NMDA negative control (doi: 10.1089/ars.2014.5993) This article has been peer-reviewed and accepted for publication, but yet to undergo copyediting proof correction. The final published version may differ from this proof. 1 Page 2 of 110 2 Abstract Aims: The in vivo pharmacology of the sigma 1 receptor (σ1R) is certainly complex; however, σ1R antagonists are of therapeutic interest because they enhance mu-opioid receptor (MOR)-mediated antinociception and reduce neuropathic pain. Thus, we investigated whether the σ1R is involved in the negative control that glutamate N- methyl-D-aspartate receptors (NMDARs) exert on opioid antinociception.
    [Show full text]
  • Pregn-5-Ene-3,20-Dione, Pregnenolone and Related Progestins on Ovulation in Pmsg-Treated Immature Rats
    EFFECT OF 5\m=infty\-DIHYDROPROGESTERONE, PREGN-5-ENE-3,20-DIONE, PREGNENOLONE AND RELATED PROGESTINS ON OVULATION IN PMSG-TREATED IMMATURE RATS B. N. SRIDHARAN, R. K. MEYER and H. J. KARAVOLAS Departments of Zoolog? and Physiological Chemistry, The Endocrinology-Reproductive Physiology Program, University of Wisconsin, Madison, Wisconsin 53706, U.S.A. (Received 9th January 1973) Summary. The facilitative effects of certain progestational steroids on ovulation were investigated by using 25-day-old female rats which had been treated on Day 22 with a non-ovulatory dose of PMSG (12 i.u.). Ovulation was caused by treatment with pregnenolone or progesterone on the morning of Day 24. The dose of pregnenolone required was higher than that ofprogesterone. Progesterone had this effect throughout the morning of Day 24, while prenenolone was only effective between 07.00 and 10.00 hours on Day 24. The two metabolites of progesterone in the hypothalamus and uterus, 5\g=a\-dihydroprogesteroneand 3\g=a\\x=req-\ hydroxy-5\m=infty\-pregnan-20-one,were also tested for their ability to cause ovulation. Although 5\g=a\-dihydroprogesteronepossessed this ability, a dose three to four times that of progesterone was required to produce a comparable effect. Doses of up to 1 \m=.\5mg 3\g=a\-hydroxy-5\g=a\-pregnan-20-one were without effect. Neither 17\g=a\-hydroxypregnenolonenor 17\g=a\-hydroxy- progesterone had any effect in influencing ovulation. Pregn-5-ene-3,20-dione had a facilitative ability comparable to that of progesterone in doses of 0\m=.\25mg or higher.
    [Show full text]